PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes
- Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER™ platform
- Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan Milner, Amadeus Capital and Astellas Venture Management